跳至主要内容
临床试验/EUCTR2020-002470-27-DE
EUCTR2020-002470-27-DE进行中(未招募)1 期

A PHASE 3, MULTICENTER, OPEN-LABEL 156-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH CHRONIC OR EPISODIC MIGRAINE

AbbVie Deutschland GmbH & Co. KG0 个研究点目标入组 670 人开始时间: 2021年4月9日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
670

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Eligible participants who completed Visit 7, and Visit 8 if applicable, of Study 3101-303-002 or Study 3101-304-002 without significant protocol deviations and who did not experience an Adverse Event that may indicate an unacceptable safety risk.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 639
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 31

排除标准

  • - Participants requiring any medication, diet, or nonpharmacological treatment on the list of prohibited concomitant medications or treatments that cannot be discontinued or switched to an allowable alternative.
  • -Participants with an ECG indicating clinically significant abnormalities at Visit 1.
  • -Participants with hypertension at Visit 1.
  • -Participants with a significant risk of self-harm, or of harm to others; participants who report suicidal ideation with intent, with or without a plan, since the last visit, must be excluded.
  • -Participants with clinically significant hematologic, endocrine, cardiovascular, pulmonary, renal, hepatic, gastrointestinal, or neurologic disease.

研究者

相似试验

进行中(未招募)
1 期
Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraineChronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine)MedDRA version: 20.0Level: HLTClassification code 10027603Term: Migraine headachesSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: LLTClassification code 10066636Term: Chronic migraineSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 22.0Level: LLTClassification code 10082019Term: Episodic migraineSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10052787Term: Migraine without auraSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10027607Term: Migraine with auraSystem Organ Class: 10029205 - Nervous system disorders
EUCTR2020-002470-27-NLAbbVie Deutschland GmbH & Co. KG670
进行中(未招募)
1 期
Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraineChronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine)MedDRA version: 20.0Level: HLTClassification code 10027603Term: Migraine headachesSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: LLTClassification code 10066636Term: Chronic migraineSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 22.0Level: LLTClassification code 10082019Term: Episodic migraineSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10052787Term: Migraine without auraSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10027607Term: Migraine with auraSystem Organ Class: 10029205 - Nervous system disorders
EUCTR2020-002470-27-DKAbbVie Deutschland GmbH & Co. KG670
招募中
3 期
A Phase 3, Multicenter, Open-Label 156-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants with Chronic or Episodic MigraineHeadache10019231Migraine
NL-OMON54251AbbVie Deutschland GmbH & Co. KG5
进行中(未招募)
1 期
Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraineChronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine)MedDRA version: 22.0Level: LLTClassification code: 10082019Term: Episodic migraine Class: 10029205MedDRA version: 20.0Level: HLTClassification code: 10027603Term: Migraine headaches Class: 10029205MedDRA version: 20.0Level: PTClassification code: 10052787Term: Migraine without aura Class: 100000004852MedDRA version: 20.0Level: PTClassification code: 10027607Term: Migraine with aura Class: 100000004852MedDRA version: 21.1Level: LLTClassification code: 10066636Term: Chronic migraine Class: 10029205MedDRA version: 20.0Level: PTClassification code: 10027599Term: Migraine Class: 100000004852
CTIS2023-507096-21-00AbbVie Deutschland GmbH & Co. KG596
进行中(未招募)
1 期
Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraine
EUCTR2020-002470-27-CZAbbVie Deutschland GmbH & Co. KG670
Phase 3 Open label clinical trial with oral... | 临床试验